These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31239121)

  • 1. Therapeutic strategies for type 2 diabetes mellitus in women after menopause.
    Paschou SA; Marina LV; Spartalis E; Anagnostis P; Alexandrou A; Goulis DG; Lambrinoudaki I
    Maturitas; 2019 Aug; 126():69-72. PubMed ID: 31239121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menopause and diabetes: EMAS clinical guide.
    Slopien R; Wender-Ozegowska E; Rogowicz-Frontczak A; Meczekalski B; Zozulinska-Ziolkiewicz D; Jaremek JD; Cano A; Chedraui P; Goulis DG; Lopes P; Mishra G; Mueck A; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Tuomikoski P; Paschou SA; Anagnostis P; Lambrinoudaki I
    Maturitas; 2018 Nov; 117():6-10. PubMed ID: 30314563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes in Menopause: Risks and Management.
    Paschou SA; Anagnostis P; Pavlou DI; Vryonidou A; Goulis DG; Lambrinoudaki I
    Curr Vasc Pharmacol; 2019; 17(6):556-563. PubMed ID: 29938620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes.
    Gorgojo Martínez JJ
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():8-16. PubMed ID: 28760227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update.
    Paschou SA; Papanas N
    Diabetes Ther; 2019 Dec; 10(6):2313-2320. PubMed ID: 31549295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs for type 2 diabetes mellitus: what is their place in therapy?
    Krentz AJ; Patel MB; Bailey CJ
    Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
    Wolverton D; Blair MM
    Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.